title: [Lactobacillus rhamnosus GG supplementation to reduce side-effects of anti-Helicobacter pylori treatment].
abstract: BACKGROUND
  Helicobacter pylori (Hp) eradication fails in about 10% of patients because of the occurrence of resistance to antibiotics and side-effects. During anti H.pylori therapy, probiotics have been used to reduce the incidence of side-effects.
  
  
  OBJECTIVE
  To determine whether adding the probiotic Lactobacillus rhamhousus GG to an anti-H. pylori regimen could help to prevent or minimize the gastrointestinal side-effect burden.
  
  
  METHODS
  66 subjects screening positive for H. pylori infection (male/female: 45/21, mean age 56,6 DS ± 16,7 year ), 59 subjects receiving 7 days of Omeprazole 20 mg b.i.d, Amoxicillin 1000 mg b.i.d and Clarithromycin 500 mg b.i.d were randomly assigned to Lactobacillus rhamnosus GG (6 x 9 ufc b.i.d ) (n = 29) or placebo (n = 30). Patients completed questionnaires after the treatment to determine the type and 10 severity of side-effects.
  
  
  RESULTS
  Side effects occurred mainly during the eradication therapy; none of them caused therapy discontinuation. Bloating, diarrhea, taste disturbance and epigastric discomfort were the most frequent side effects: (10.3% versus 16%, 13.8% versus 20%, 13.7% versus 20% and 13.7 % versus 20% respectively). No significant differences were found between the two groups for individual symptoms.
  
  
  CONCLUSIONS
  In this study, probiotic supplementation did not diminish significantly the frequency of new or aggravated symptoms during H. pylori eradication.
authors.affiliation: Departamento de Gastroenterología, Hospital Universitario Arnaldo Milián Castro, Santa Clara, Villa Clara, Cuba. ipm4712@capiro.vcl.sld.cu
authors.forename: Maykel
authors.initials: M
authors.lastname: Padilla Ruiz
authors.forename: María Emilia
authors.initials: ME
authors.lastname: Fernández Aguiar
authors.forename: Merlyn
authors.initials: M
authors.lastname: Arce Nuñez
authors.forename: Roberto
authors.initials: R
authors.lastname: Polo Amorín
mesh_terms: D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D019587:Dietary Supplements; D064420:Drug-Related Side Effects and Adverse Reactions / Q000517:prevention & control; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D052201:Lacticaseibacillus rhamnosus; D008297:Male; D008875:Middle Aged; D019936:Probiotics / Q000627:therapeutic use*; D011446:Prospective Studies; D016037:Single-Blind Method
chemical_list: D000900:Anti-Bacterial Agents